Welcure Drugs & Pharmaceuticals Limited has accepted the resignation of Ms. Palak Jain as its Company Secretary, Compliance Officer, and key managerial personnel, effective from the close of business hours on June 19, 2026. The resignation was submitted due to personal reasons and other professional commitments. The Board of Directors acknowledged the departure and recorded its appreciation for her contributions to the company.

The intimation was filed pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and related circulars. The company confirmed that there are no other material reasons for the resignation beyond those stated. The Managing Director & CFO, Chintan Didawala Ganpat, signed the regulatory disclosure.

The resignation details were provided in Annexure A of the filing. The table below summarizes the key particulars regarding the change in key managerial personnel.

In her resignation letter, Ms. Jain requested the completion of all necessary formalities, including the filing of required forms with the Ministry of Corporate Affairs and intimating relevant authorities. She expressed gratitude for the support received from the Board and senior executives during her tenure.

Welcure Drugs and Pharmaceuticals Limited reported a net loss of ₹549.01 crore for the financial year ended March 31, 2026, a significant decline from the net profit of ₹217.01 lakh recorded in the previous year. The company's total revenue from operations for FY26 was ₹2,645.99 lakh. The standalone audited financial results were reviewed by the audit committee and approved by the board of directors at a meeting held on May 29, 2026.

The company reported a net loss of ₹4,986.14 lakh for the quarter ended March 31, 2026. Total revenue from operations for the quarter was ₹146.43 lakh. The equity share capital of the company stood at ₹12,359.40 lakh as of March 31, 2026, compared to ₹1,125.12 lakh in the previous year.

Financial Performance

The following table outlines the key financial metrics for the quarter and year ended March 31, 2026:

The company's reserves, excluding revaluation reserves, were reported at negative ₹2,657.37 lakh for the year ended March 31, 2026. The financial results were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and were filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.